Canonical product evidence map
Tirzepatide Evidence Map
A source-linked map of controlled human trials, FDA labeling, mechanism records and material-identity boundaries for tirzepatide.
- 10
- unique source records
- 3
- research types
- 2022–2026
- source-year range
Evidence distribution
See the source mix before reading the conclusions.
A large record count does not imply mature human evidence. The model and source type determine which question a record can answer.
Research type
Study model
Source-linked records
10 records connected to Tirzepatide
Records are deduplicated by canonical source URL and keep their model, type and evidence-tier labels visible.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
MOUNJARO (tirzepatide) current prescribing information
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
ZEPBOUND (tirzepatide) prescribing information
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
SURPASS-1 randomized phase 3 trial
Primary clinical trial record; PMID 34186022.
Evidence boundary
A source set is not a clinical recommendation.
- Human, animal, in-vitro, analytical, registry and regulatory records remain separate evidence categories.
- A published intervention or approved finished medicine does not verify the identity or quality of a catalog research lot.
- Record inclusion does not mean every finding has been independently replicated or applies outside its stated population and model.
Continue researching